Semaglutide 5–50 mg

Semaglutide for research: identity and specifications

Semaglutide (CAS 910463-68-2) is a synthetic peptide analog of human GLP-1 (glucagon-like peptide-1), studied in laboratory research on incretin signaling and GLP-1 receptor pharmacology. Supplied in vials of 5 to 50 mg, lyophilized powder, with no fillers, carriers or excipients, at ≥98% purity by HPLC, with the lot-specific value reported on the certificate of analysis.

Scientific background

The Aib substitution at position 2 confers resistance to degradation by dipeptidyl peptidase-4 (DPP-4), and the fatty acid side chain attached to Lys26 supports reversible albumin binding, features that make it a recurring structural model in structure-activity studies of incretin analogs. In assays using cells that express the GLP-1 receptor, the compound is investigated for binding affinity, receptor activation and downstream cyclic AMP (cAMP) generation.

Preclinical literature uses semaglutide in glucose-dependent insulin secretion assays in islets and pancreatic cell lines and in rodent models of glucose metabolism, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• GLP-1 receptor binding and cAMP signaling in cell-based assays
• Glucose-dependent insulinotropic response in metabolic research models
• Structure-activity relationship of DPP-4 resistance and albumin binding
• Comparative pharmacology of GLP-1 receptor agonists in experimental models

Technical specifications

Analytical quality and chain of custody

Every lot of semaglutide is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the semaglutide supplied?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

Are semaglutide and the code NN9535 the same compound?

Yes, they are synonyms for the same GLP-1 analog, identified by PubChem CID 56843331 and molecular formula C187H291N45O59. Commercial drug names do not apply to this research reagent.

How should the compound be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase semaglutide?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA and the molecular structure in the PubChem database.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.